Comments
Drug maker Lupin on Wednesday said it has received approval from the US health regulator to sell Arformoterol Tartrate inhalation solution, used to treat chronic obstructive pulmonary disease.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of Sunovion Pharmaceuticals Inc’s Brovana inhalation solution, Lupin said in a statement.
The product is indicated for the long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
As per IQVIA’s moving annual total till Feb 2020, Arformoterol Tartrate inhalation solution had an annual sales of around $489 million in the US.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.